MedPath

Prasterone

Generic Name
Prasterone
Brand Names
Intrarosa
Drug Type
Small Molecule
Chemical Formula
C19H28O2
CAS Number
53-43-0
Unique Ingredient Identifier
459AG36T1B
Background

Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion.

In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

In Canada, a prescription is required to buy DHEA.

Indication

DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids).

DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.

Associated Conditions
Moderate Dyspareunia, Severe Dyspareunia

ANDRO 2002: Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction

Phase 2
Completed
Conditions
Erectile Dysfunction
First Posted Date
2005-09-20
Last Posted Date
2016-01-13
Lead Sponsor
Queen's University
Target Recruit Count
120
Registration Number
NCT00202163
Locations
🇨🇦

Centre for Advanced Urological Research, Kingston, Ontario, Canada

Effects of DHEA and Exercise in the Elderly

Phase 3
Completed
Conditions
Healthy Volunteers
First Posted Date
2005-09-20
Last Posted Date
2006-01-06
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
64
Registration Number
NCT00205686
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Effects of Dehydroepiandrosterone (DHEA) in Humans

Phase 3
Completed
Conditions
Aging
First Posted Date
2005-09-16
Last Posted Date
2008-08-25
Lead Sponsor
National Institute on Aging (NIA)
Target Recruit Count
142
Registration Number
NCT00182975
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
First Posted Date
2005-09-16
Last Posted Date
2016-05-18
Lead Sponsor
University of Michigan
Target Recruit Count
13
Registration Number
NCT00189124
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Efficacy and Safety of DHEA for Myotonic Dystrophy

Phase 2
Completed
Conditions
Myotonic Dystrophy
First Posted Date
2005-09-14
Last Posted Date
2010-04-06
Lead Sponsor
University of Versailles
Target Recruit Count
75
Registration Number
NCT00167609
Locations
🇫🇷

Institut de myologie, Paris, France

🇫🇷

CHU, Toulouse, France

🇫🇷

Raymond Poincaré Hospital, Garches, France

and more 1 locations

Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly

Not Applicable
Completed
Conditions
Healthy
First Posted Date
2005-05-27
Last Posted Date
2009-12-11
Lead Sponsor
National Institute on Aging (NIA)
Target Recruit Count
144
Registration Number
NCT00111930
Locations
🇺🇸

University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

Phase 2
Completed
Conditions
Crohn's Disease
First Posted Date
2005-03-23
Last Posted Date
2007-10-19
Lead Sponsor
Inflabloc Pharmaceuticals
Target Recruit Count
75
Registration Number
NCT00106314
Locations
🇺🇸

Northwest Gastroenterologists, Arlington Heights, Illinois, United States

🇨🇦

Gastrointestinal Research Institute, Vancouver, British Columbia, Canada

🇨🇦

IBD Clinical and Research Centre, Winnipeg, New Brunswick, Canada

and more 35 locations

Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans

Not Applicable
Completed
Conditions
Aging
Obesity
Insulin Resistance
First Posted Date
2004-12-20
Last Posted Date
2009-12-11
Lead Sponsor
National Institute on Aging (NIA)
Target Recruit Count
56
Registration Number
NCT00099697
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Phase 3
Completed
Conditions
Systemic Lupus Erythematosus
First Posted Date
2004-07-16
Last Posted Date
2008-01-14
Lead Sponsor
Genelabs Technologies
Target Recruit Count
114
Registration Number
NCT00082511
Locations
🇺🇸

Wallace Rheumatic Study Center, Los Angeles, California, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 19 locations

Dehydroepiandrosterone Effects on HIV-1 Replication

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2003-07-18
Last Posted Date
2006-08-18
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Target Recruit Count
40
Registration Number
NCT00065104
Locations
🇺🇸

Community Consortium, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath